Inpharma Weekly

, Volume 1486, Issue 1, pp 14–14 | Cite as

Amrubicin + cisplatin “impressive” for untreated advanced SCLC

Clinical study
  • 4 Downloads

Keywords

Lung Cancer Survival Rate Neutropenia Survival Time Median Survival 

Copyright information

© Adis International Ltd 2005

Personalised recommendations